Vendor Intelligence Report: Kerui Peptide HongKong

Published 3 Jul 2026. 22-page investigative report on who is behind Kerui Peptide HongKong: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 6 Finnrick lab tests, Kerui Peptide HongKong records 2 passes and 4 failures, for a 33% overall pass rate. The testing record is narrow—only retatrutide has Finnrick data—but it is still actionable: Kerui is not an unobserved vendor, yet its retatrutide profile is fail-heavy and becomes less forgiving under stricter grading. Buyers choosing specifically for retatrutide should treat current-lot verification as mandatory, not optional.

The corporate picture is mixed rather than blank. The report verifies a live Hong Kong company record, but the domain trail and sales context point toward mainland-China operations, while website claims include recycled or weakly corroborated material. A broken products page exposing d:\freehost\kerui9y23 adds an operational-brittleness signal at the same time forum sales continue.

Kerui’s strongest public footprint is forum-based: Emily-KR appears as the active GLP-1 Forum persona with sponsor status, while Iris1 promotes Kerui in an Anabolex China-supplier lane with a broader direct-message catalog. That makes the brand easier to observe than a pure Telegram seller, but harder to authenticate across reps, private channels, and payment routes.

For U.S.-bound GLP-1 buyers, the risk is not only chemistry. FDA Import Alert 66-80 and China/Hong Kong peptide enforcement make non-delivery and detention material, and the payment setup leans toward crypto and bank rails with limited practical recourse. The public finding is directional: Kerui is a weak first-choice retatrutide source unless the exact batch can be independently verified.

Inside the full report:

  • Appendix A laboratory breakdown and methodology-divergence charts for Kerui’s retatrutide record
  • Hong Kong registry capture, registered-address analysis, and unresolved ownership leads
  • WHOIS, domain-expiry, and hosting-path evidence from the live keruihk.com site
  • Forum persona map covering Emily-KR, Iris1, mofy55/Mofy, and channel-authentication risk
  • Payment-rail review across crypto networks, fiat bank options, and private-message ordering
  • Regulatory analysis of FDA Import Alert 66-80, CBP peptide seizures, and Hong Kong anti-obesity-drug enforcement

Risk assessment

  • Retatrutide quality and consistency risk — high: Finnrick’s current record for Kerui covers retatrutide only: 6 tests with 2 pass / 4 fail and a 66.31% rating.
  • GLP-1 import seizure and enforcement risk — high: Retatrutide, tirzepatide, and semaglutide intersect FDA Import Alert 66-80 DWPE and China/Hong Kong peptide enforcement, raising non-delivery risk.
  • Corporate/location and catalog-transparency risk — medium: Hong Kong entity is verified, but keruihk.com registrant data points to Jilin, the public site is sanitized, and forum channels market a broader PED/SARM catalog.
  • Channel-authentication and persona-confusion risk — medium: Kerui uses multiple personas, including Emily-KR, Iris1, and mofy55/Mofy, plus private contact channels without a consolidated official-channel or anti-counterfeit verification system in the materials.
  • Irreversible-payment and limited-recourse risk — medium: Forum materials list crypto across ERC20/TRC10/TRC20 and bank transfers in multiple currencies, leaving buyers with limited chargeback recourse if retatrutide fails or GLP-1 shipments are seized.